Collaborations

To advance our mission of providing clinical diagnostics to improve patient outcomes SpeeDx collaborate with partners across the diagnostic space. PlexPCR® technology has helped transform infectious disease diagnostics, as well as significantly impacting cancer diagnosis and treatment.

Biocartis

Significant improvements in the diagnosis and treatment of cancer have occurred through a licensing partnership with Biocartis. PlexPCR® drives the market-leading multiplex capability in the Biocartis Idylla™ platform.

  • Using PlexZyme® and PlexPrime® PCR in the testing cartridge, Idylla™ can detect over 50 gene mutations in a tumour biopsy (FFPE, blood or plasma).
  • PlexPCR® provides high specificity and sensitivity (Limit of Detection of < 1% and as low as 0.01%), ideal for liquid biopsy testing where DNA material is limited.
Biocartis Idylla instrument
Scientist using MG FleXible product

Cepheid

SpeeDx partnered with Cepheid as a trusted reagent manufacturer (TRM) under their FleXible Cartridge program, aimed at accelerating menu expansion on the Cepheid GeneXpert systems.

The first test, ResistancePlus® MG FleXible, launched October 2019, detecting the sexually transmitted infection (STI) Mycoplasma genitalium (Mgen) and markers associated with azithromycin resistance.

News:

GSK

SpeeDx signed a collaboration agreement with GSK to provide tests and custom test development to support antibiotic clinical trials and new product development.

News:

GSK logo on building
LabCorp Logo

LabCorp

SpeeDx and LabCorp are working together to develop and introduce new tests with the promise to help improve patient care, focusing on women’s health and infectious diseases.

News:

Roche

SpeeDx partnered with Roche, a global pioneer in pharmaceuticals and diagnostics, to expand access to infectious disease and antibiotic resistance tests and technology. Under the terms of the agreement, Roche has non-exclusive access to SpeeDx existing tests and technology for the management of antibiotic resistance in STIs, to quickly bring new products to a broader group of patients around the world.

News:

View Products from Roche:

Roche logo

  • “QuantuMDx is always looking to expand the portfolio of diagnostic tests available on the Q-POC™ platform, and this collaboration with SpeeDx is an obvious choice given the proven compatibility of their robust chemistry across a range of platform technologies.”

    Jonathan O’Halloran, Chief Scientific Officer at QuantuMDx Group

  • “The availability of ResistancePlus® MG in a FleXible cartridge that runs on the GeneXpert® System is a compelling and exciting extension for us.”

    Colin Denver, CEO of SpeeDx

  • "The game-changing real-time PCR based technology uses a unique combination of PlexZyme® and PlexPrime®, which allows very high sensitivity and specificity combined with high multiplexing capability."

    Biocartis

Learn more about our collaborations & partnerships